ERYPHARM

Company Overview

EryPharm is a biotech startup created in 2016 and a spin-off from Sorbonne University. EryPharm is the entrepreneurial extension of academic research carried out by Prof. Luc Douay’s team, which pioneered all stages of fundamental research of cultured red blood cells (cRBCs) and started the concept of cRBCs in vivo in animals in 2002. In 2005, they described the generation of cRBCs in vitro from human hematopoietic stem cells (HSC) while the first human injection of cRBCs in 2011 demonstrated the proof of the concept and the potential of cRBCs’ technology compared to native RBCs. In 2022, clinical trials will run to confirm the product’s non-toxicity, to be followed by trials in 2023 to confirm the benefits of cRBCs. Go to Market authorization is expected in 2028 at the latest.

Company's Business Segments

• Cultured Red Blood Cells : The company develops cRBCs as a complement to blood donation, offering a potential new blood transfusion product with advantages over traditional donated blood.